Servier is an international pharmaceutical company governed by a non-profit organisation, with headquarters in France. The company's vision is to put patients and innovation at the heart of all its actions. To respond to the growing need for therapeutic solutions, Servier has made oncology one of its foremost priorities, investing 50% of its R&D budget in the field with a focus on solid tumours and haematological malignancies. As a company committed to therapeutic progress to serve patient needs, Servier has chosen to focus in two promising areas of oncology—immunotherapy and apoptosis. Other areas of research interest include cardiometabolic, immune-inflammatory and neurodegenerative diseases.

M-NO-UK-00890

January 2022